Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacopeia is to work with Allergan to evaluate ocular disease compounds. The partnership hopes to develop compounds which will represent a novel treatment option for the "wet" form of age-related macular degeneration.
Subscribe to our email newsletter
Wet age-related macular degeneration is currently the leading cause of vision loss in adults over 55 years of age.
The agreement resulted in an upfront cash payment from Allergan to Pharmacopeia, and may result in preclinical and clinical payments, plus milestone payments and royalties on drugs developed by Allergan in the field of ophthalmology. Pharmacopeia has retained rights to other therapeutic areas.
“We are working with Allergan to investigate alternate mechanistic approaches that could complement or potentially improve upon existing therapies,” said Dr David Floyd, chief scientific officer of Pharmacopeia.